TIDMOCTP
RNS Number : 8098A
Oxford Cannabinoid Tech.Holdings
07 February 2022
7 February 2022
Oxford Cannabinoid Technologies Holdings plc
("OCTP", or the "Company")
Notice of Interim Results
&
Analyst and Investor Presentations
Oxford Cannabinoid Technologies Holdings plc (LSE: OCTP, OTCQB:
OCTHF), the pharmaceutical company developing prescription
cannabinoid medicines for approval by global regulatory agencies
and targeting the US$ multi-billion pain market, intends to
announce results for the half year ended 30 November 2021 on
Tuesday 22 February 2022.
Analyst Briefing, 9:30 a.m., Tuesday 22 February 2022
A briefing for Analysts will be held at 9:30 a.m. GMT on the day
of the results.
Analysts interested in attending should contact Walbrook PR by
emailing oxcantech@walbrookpr.com or by calling 020 7933 8780.
Investor Presentation, 4:30 p.m., Tuesday 22 February 2022
A live online presentation via the Investor Meet Company
platform will also be held at 4:30 p.m. GMT on Tuesday 22 February
2022, which is open to all existing and potential shareholders.
Questions can be submitted pre-event via the 'Investor Meet
Company' dashboard up until 9:00 a.m. the day before the meeting or
at any time during the live presentation. Investors can sign up to
Investor Meet Company for free and add to meet Oxford Cannabinoid
Technologies Holdings plc via:
https://www.investormeetcompany.com/oxford-cannabinoid-technologies-holdings-plc/register-investor
Investors who already follow OCTP on the Investor Meet Company
platform will automatically receive an invitation to the event.
Shares & AJ Bell Investor Evening: Wednesday 23 February
2022
John Lucas, CEO, will be presenting at the Shares and AJ Bell
investor evening webinar on Wednesday 23 February 2022, covering
the Company's half year results and future prospects. Participants
will have the chance to ask questions online after the
presentation.
Existing and potential shareholders can register to join the
webinar for free via:
https://www.sharesmagazine.co.uk/events/event/shares-investor-webinar-230222
The Directors of the Company accept responsibility for the
content of this announcement.
Enquiries:
Oxford Cannabinoid Technologies +44 (0)20 3034 2820
Holdings plc john@oxcantech.com
Dr John Lucas (CEO) clarissa@oxcantech.com
Clarissa Sowemimo-Coker (COO)
Cairn Financial Advisers LLP
Emily Staples +44 (0)20 7213 0897
Jo Turner +44 (0) 20 7213 0885
Walbrook PR Limited +44 (0)20 7933 8780
Paul Vann +44 (0)7768 807631
Nicholas Johnson oxcantech@walbrookpr.com
Harbor Access LLC (US/OTCQB +1 (203) 862 0492
enquiries) Richard.Leighton@harboraccessllc.com
Jonathan Paterson
Richard Leighton
About Oxford Cannabinoid Technologies Holdings Plc :
Oxford Cannabinoid Technologies Holdings plc is the holding
company of Oxford Cannabinoid Technologies Ltd, a pharmaceutical
company developing prescription cannabinoid medicines for approval
by key medicines regulatory agencies worldwide and targeting the U$
multi-billion pain market (together the "Group"). Cannabinoids are
compounds found in the cannabis plant that have been shown to have
a range of therapeutic effects on the body, including pain relief.
The Group has a clearly defined path to commercialisation, revenues
and growth. The Group is developing drug candidates through
clinical trials to gain regulatory approval (FDA/MHRA/EMA) that
will enable medical professionals to prescribe them with
confidence.
The Group's portfolio aims to balance risk, value and time to
market, whilst ensuring market exclusivity around all its key
activities. The Group's lead compound, OCT461201, is a highly
potent and selective CB2 agonist and is being developed by OCT in a
solid oral dosage form. OCT is conducting pre-clinical testing and
development with clinical trials scheduled for Q1 2023. The Group's
product pipeline also uses a balanced drug product strategy that
employs both natural and synthetic compounds for the treatment of
rare diseases and includes chemically modified phytocannabinoids
with improved drug-like characteristics and a proprietary library
of cannabinoids.
OCTP operates a partnership model with external academic and
commercial partners.
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi ed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward-looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements re ect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORUPUMAPUPPGCQ
(END) Dow Jones Newswires
February 07, 2022 01:59 ET (06:59 GMT)
Oxford Cannabinoid Techn... (LSE:OCTP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oxford Cannabinoid Techn... (LSE:OCTP)
Historical Stock Chart
From Sep 2023 to Sep 2024
